¶ Zymeworks
.png)
Zymeworks is a Canadian biotechnology company based in Vancouver, British Columbia. The company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases.
¶ History
In 2011, Merck entered an agreement with Zymeworks to use their Azymetric™ platform for the development and commercialization of bispecific antibodies against targets in multiple therapeutic fields.[1] The arrangement involved the joint development and improvement of the platform, as well as Merck taking the resulting novel antibody products through clinical development.[2]
¶ Organization
Lumira Ventures is an investor in Zymeworks.[3]
¶ External links
Merck & Co. Seals Bispecific Antibody Collaboration with Zymeworks. (2011, August 29). GEN - Genetic Engineering and Biotechnology News. http://archive.today/2022.04.28-152140/https://www.genengnews.com/topics/drug-discovery/merck-co-seals-bispecific-antibody-collaboration-with-zymeworks/ ↩︎
FOI Request - HTH-2015-51828. (2016, February 12). Government of British Columbia. https://web.archive.org/web/20220428045844/http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2015-51828.pdf ↩︎
Portfolio. Lumira. Retrieved March 26, 2023, from https://web.archive.org/web/20230326213612/https://www.lumiraventures.com/portfolio-companies/ ↩︎